The obvious and inevitable risk of the proposal is that companies will act to innoculate their larger and more lucrative market by not launching or significantly delaying the launch of new medicines in Australia. They may even be forced to consider removing already reimbursed medicines. …
Latest Video
New Stories
-
PHARMAC switch now blamed for three deaths
November 14, 2019 - - Latest News -
7CPA deal unlikely in 2019
November 14, 2019 - - Latest News -
New report highlights system challenge for Alzheimer's treatment
November 14, 2019 - - Latest News -
Official opening of new Merck headquarters
November 13, 2019 - - Latest News -
AusBiotech releases update on local regenerative medicine sector
November 13, 2019 - - Latest News -
Department confirms emergency supply arrangements for bushfire areas
November 13, 2019 - - Latest News -
Mark Glover: The tech opportunity for clinical trials
November 13, 2019 - - Latest News